Skip to main content

Vasculitis

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Nov 30, 2020

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events. Virtually every vasculitis patient treated with traditional glucocorticoid regimes suffers from these. These are not

Read Article
"The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis" by Dr. Richard Conway ( @RichardPAConway) https://t.co/VG1ah3Nq5c https://t.co/jORhfQn3EC
Dr. John Cush RheumNow ( View Tweet)
Nov 17, 2020
Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh #ACR20 https://t.co/kJxdgoL5EI https://t.co/uYUwUr53lL
Dr. John Cush RheumNow ( View Tweet)
Nov 17, 2020
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/HrMGvqcNC4
Dr. John Cush RheumNow ( View Tweet)
Nov 16, 2020
San Diego-based rheumatologist Dr. Arthur Kavanaugh takes a closer look at Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis #ACR20. https://t.co/53gQ0dLjU7

Dr. John Cush RheumNow ( View Tweet)

Nov 12, 2020

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Nov 10, 2020

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Evolution of GCA Treatments - More to Come by Meral El Ramahi ( @MeralElRamahiMD) #ACR20 Reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA) https://t.co/xuQ7Litn8t https://t.co/4NtVSMOPsS
Dr. John Cush RheumNow ( View Tweet)
Nov 10, 2020
GCA Treatment Data: Dr. David Liew Abstract ( @drdavidliew) Dr. David Liew reviews abstracts #0516 and #0513 presented at the #ACR20 annual meeting. https://t.co/KmjTRmDbA1

Dr. John Cush RheumNow ( View Tweet)

Nov 10, 2020
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/kwXUhn8QSG https://t.co/OjTtFE6jEt
Dr. John Cush RheumNow ( View Tweet)
Nov 10, 2020
Dr P Seo notes based on PEXIVAS study while PLEX does not seem to help with AAV, it showed you can drop steroid dose sooner: start pred 1 mg/kg/d but drop down after 1 week to 0.5 mg/kg/d #ACRReview #ACR20 @rheumnow
Nov 10, 2020
And we're off! #ACR20 year in review ⭐️@philseo's #Vasculitis lecture⭐️ Take home lessons/ remaining questions from GiACTA ⬇️ #ACRambassador https://t.co/7C9QxbUeNH
Elizabeth Graef SituationRheum ( View Tweet)
Nov 10, 2020
📌More #Vasculitis pearls from #ACR20 Year in Review #PEXIVAS in a nutshell ⬇️ #ACRambassador https://t.co/PnoP7QIiYs
Elizabeth Graef SituationRheum ( View Tweet)
Nov 10, 2020
There are a number of important mimics of IgG4-RD that should be considered 🔵ANCA-associated vasculitis 🔵Multicentric Castleman’s disease 🔵Rosai-Dorfman disease 🔵Inflammatory myofibroblastic tumour 🔵Cutaneous plasmacytosis 🔵Erdheim-Chester disease 🔵Malignancy #ACR20

Chris Wincup chriswincup ( View Tweet)

Nov 10, 2020

Answering questions on how COVID-19 affects rheumatic patients

Nov 10, 2020

As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.

Read Article
TAK & GCA differ in vessel involvement when it comes to the 👁👁 > TAK- large vessel lesions > GCA- small vessel vasculitis @RheumNow #ACR20 https://t.co/sa4VEvCKOt
Nov 09, 2020
@RheumNow #ACR20 abs1923 prosp cohort study of angiographic lesions in Takayasu’ &GCA: although infrequent new angio lesions more likely in TAK. Improvement is possible in both conditions, more likely to occur in TAK.
Olga Petryna DrPetryna ( View Tweet)
Nov 09, 2020
Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% Enormous potential, worth exploring! Cid et al #ACR20 ABSTL06 @RheumNow
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
Can you give TCZ for GCA with minimal steroids? Everyone hates steroids, right? GUSTO trial: IVMP 500mg x3d +TCZ sc q1w 14/18 achieved clinical remission at 24w (but mean 11w) 13/18 relapse-free 1/18 permanent visual loss Is that tradeoff worth it? #ACR20 ABST0515 @RheumNow
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow

David Liew drdavidliew ( View Tweet)

Nov 09, 2020
RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no.
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe

Bella Mehta bella_mehta ( View Tweet)

Nov 09, 2020
RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2020
L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new or relapsing/ref pts, No diff in AE #ACR20 #ACRambassador

Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)

Nov 09, 2020
SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2020
The avacopan story, stronger again: (recall: avacopan targets C5aR) endogenous anti-C5aR1 in GPA inversely correlates with dx activity, relapse questions, via chair @philseo: What happens to anti-C5aR1 with Rx? Does this influence therapeutic strategy? #ACR20 ABST2050 @RheumNow
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
×